Nyxoah Appoints John Landry as Chief Financial Officer
Current CFO, Loïc Moreau, to Transition into Role of President International
Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market.
Mr. Landry brings over two decades of financial leadership experience in the healthcare and medtech sectors, with a proven track record of driving growth and operational efficiency in public and private companies. Most recently, he served as CFO at Vapotherm Inc., where he played an instrumental role in executing financial strategies that supported significant revenue growth and market share expansion in the U.S. market.
'We are delighted to welcome John to Nyxoah. His deep financial expertise and extensive experience in the U.S. healthcare landscape in combination with his strong investor relations experience will be invaluable as we accelerate our growth in this critical market,' said Olivier Taelman, CEO of Nyxoah. 'John's leadership will help us further optimize our financial strategies and drive operational efficiencies as we prepare Genio for commercialization in the US.'
Additionally, Nyxoah announces that Loïc Moreau, currently CFO, will transition into the newly created role of President International. In this capacity, Mr. Moreau will spearhead Nyxoah's global expansion efforts, focusing on strengthening the Company's presence in key international markets.
This announcement reflects Nyxoah's commitment to building a strong, diversified leadership team to support its ambitious growth objectives.
About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
FORWARD-LOOKING STATEMENTS
Certain statements, beliefs and opinions in this press release are forward-looking, reflecting Nyxoah's current expectations and beliefs regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah's goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and potential receipt of FDA approval and entrance into the U.S. market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of Nyxoah's Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission ('SEC') on March 20, 2024, and subsequent reports that Nyxoah files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither Nyxoah nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
Contacts:
Nyxoah
Loïc Moreau
IR@nyxoah.com
For Media
In United States
FINN Partners – Glenn Silver
glenn.silver@finnpartners.com
In Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be
In International/Germany
MC Services – Anne Hennecke
nyxoah@mc-services.eu
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Biz Bahrain
15 hours ago
- Biz Bahrain
Formula 1 and Allwyn to launch community award programme
Formula 1, together with leading multi-national lottery-led entertainment company and Official Partner Allwyn, will celebrate and spotlight community-focused initiatives around the world with the new F1® Allwyn Global Community Award. The brand-new programme, created as part of the two organisations' multi-year partnership and as part of their shared commitment to driving positive change, will celebrate local initiatives that leave a positive impact on society. The winners, who will receive a €100,000 donation along with a bespoke trophy and the chance to visit a Formula 1 Grand Prix, must address one or more of the following focus areas: empowerment and inclusion; education and opportunity; health and wellbeing, and sustainability and innovation. Ahead of each selected Grand Prix, the local promoter will identify community-focused initiatives supported by the F1 ecosystem that have had a meaningful impact, and a panel of judges from Formula 1, Allwyn, and a representative from the local race community will select a winner. This year, the first award will be presented at the FORMULA 1 HEINEKEN DUTCH GRAND PRIX 2025, taking place between 29 – 31 August, with subsequent winners awarded at the United States, Mexico, and Las Vegas Grands Prix. Stefano Domenicali, President & CEO of Formula 1, said: 'It is a pillar of our sport to leave a positive legacy where we race and for many years we've worked with the promoters and regional organisations to do just that, from inviting children from local schools to the track to encourage them to consider a role in motorsport, through to funding education initiatives and welcoming local community outlets and charities to be part of the event. Every year 24 incredible venues open their doors to host us, and we are met with fantastic passion and love at the track and throughout the entire city, so I am very proud to launch the F1 Allwyn Global Community Award as part of our mission. We will give the local initiatives that go the extra mile for making their communities and make the world a better place the recognition and global platform they deserve.' Robert Chvátal, Group CEO of Allwyn, said: 'Championing positive impact is at the heart of what we do at Allwyn. Our partnership with Formula 1 is the perfect chance to demonstrate our commitment to communities through the creation of this inspiring F1 Allwyn Global Community Award, supporting the very best community initiatives around the world and bringing them to a huge global audience.'
Gulf Insider
a day ago
- Gulf Insider
Scientists Reveal Your Morning Coffee Flips An Ancient Longevity Switch
Caffeine appears to do more than perk you up—it activates AMPK, a key cellular fuel sensor that helps cells cope with stress and energy shortages. This could explain why coffee is linked to better health and longer life. A new study from the Cellular Ageing and Senescence laboratory at Queen Mary University of London's Cenfre for Molecular Cell Biology, reveals how caffeine — the world's most popular neuroactive compound — might do more than just wake you up. The study in the journal Microbial Cell shows how caffeine could play a role in slowing down the ageing process at a cellular level. Caffeine has long been linked to potential health benefits, including reduced risk of age-related diseases. But how it works inside our cells, and what exactly are its connections with nutrient and stress responsive gene and protein networks has remained a mystery — until now. In new research published by scientists studying fission yeast — a single-celled organism surprisingly similar to human cells — researchers found that caffeine affects ageing by tapping into an ancient cellular energy system. A few years ago, the same research team found that caffeine helps cells live longer by acting on a growth regulator called TOR (Target of Rapamycin). TOR is a biological switch that tells cells when to grow, based on how much food and energy is available. This switch has been controlling energy and stress responses in living things for over 500 million years. But in their latest study, the scientists made a surprising discovery: caffeine doesn't act on this growth switch directly. Instead, it works by activating another important system called AMPK, a cellular fuel gauge that is evolutionarily conserved in yeast and humans. 'When your cells are low on energy, AMPK kicks in to help them cope,' explains Dr Charalampos (Babis) Rallis, Reader in Genetics, Genomics and Fundamental Cell Biology at Queen Mary University of London, the study's senior author. 'And our results show that caffeine helps flip that switch.' Interestingly, AMPK is also the target of metformin, a common diabetes drug that's being studied for its potential to extend human lifespan together with rapamycin. Using their yeast model, the researchers showed that caffeine's effect on AMPK influences how cells grow, repair their DNA, and respond to stress — all of which are tied to ageing and disease. 'These findings help explain why caffeine might be beneficial for health and longevity,' said Dr John-Patrick Alao the postdoctoral research scientist leading this study. 'And they open up exciting possibilities for future research into how we might trigger these effects more directly — with diet, lifestyle, or new medicines.' So, the next time you reach for your coffee, you might be doing more than just boosting your focus — you could also be giving your cells a helping hand.
Gulf Insider
a day ago
- Gulf Insider
New Stem Cell Therapy Shows 'Promising' Results For Treating Hair Loss In Preclinical Trials
Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. A recent study analyzed the effect of injecting mice's skin with stem cells from human fat — 'adipose-derived stem cells (ASCs)' — as a means of treating androgenetic alopecia (AGA), more commonly known as male- or female-pattern hair loss. The team found that male mice achieved the best hair regrowth after three weeks when they received low-dose ASCs, combined with an energy-boosting molecule called adenosine triphosphate (ATP). Low-dose and high-dose ASC treatments along with ATP led to no hair regrowth improvement in females, but medium-dose ASC plus ATP led to greater regrowth. The researchers concluded that hair regrowth was improved in 'all experimental groups' where male mice received stem cell solutions supplemented with ATP. Researchers at the San Carlos Clinical Hospital in Madrid may have targeted a potential solution for hair loss. (iStock) The findings were published in the journal Stem Cell Research & Therapy. Lead study author Dr. Eduardo López Bran — dermatologist and professor at The Complutense University of Madrid — shared his expectations for the study in an interview with Fox News Digital. 'We expected good results, but not such a high level of success,' he said. 'We're talking about a very high degree of hair regrowth in both male and female mice.' With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. With appropriate doses, the researchers achieved 'very high percentages' of hair regrowth, noting that 100% of the male mice and up to 90% of the female mice regrew hair. (Actual mice from the study not pictured.) (iStock) 'These results demonstrate that advanced therapies may represent a new therapeutic approach for many diseases for which no effective treatments are currently available,' Bran went on. 'Achieving such promising results in the preclinical phase with a completely novel approach to androgenetic alopecia — one that avoids chronic treatment and is also safe — is a significant scientific milestone.' 'We're talking about a very high degree of hair regrowth in both male and female mice.' The main limitation of the study was the thinness of mouse skin, Bran noted, which 'posed a challenge in administering the therapy.' 'This required the development of protocols to minimize experimental variability, and will be a key factor when studies in humans begin,' he said. 'Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits.' (iStock) These new findings should be 'interpreted with caution and scientific rigor,' Bran cautioned. 'Although the results in mice represent significant progress, it is also true that it is essential to wait for clinical benefits in humans to be confirmed.' The researcher encouraged those with androgenetic alopecia to continue consulting with their dermatologists and to follow prescribed treatments as research develops. 'It is important to remain hopeful. Research advances are pointing toward possible solutions that, in the future, may offer long-lasting results without the need for continuous treatment to maintain benefits,' Bran added. 'This study is small, and more research is needed on this method as a potential treatment option.' Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia, the researcher noted. 'If everything progresses as expected, the most optimistic timeline points to the treatment becoming available in approximately five years,' he said. Looking ahead to human clinical trials, researchers are 'actively working' on confirming safety for men and women between 18 and 50 years old with moderate androgenetic alopecia. (iStock) In a separate interview with Fox News Digital, Dr. Brendan Camp, M.D., a New York-based dermatologist who was not involved in the study, commented on the potential for this method. 'While not commercially available, this study suggests that injection of stem cells supplemented with ATP into scalp skin could potentially encourage hair regrowth in individuals with androgenetic alopecia,' he reiterated.
